Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
The Ayala Pharmaceuticals, Inc. (ADXS) news stream captures the company’s evolution as a clinical-stage oncology developer focused on small molecule therapeutics and related platforms for rare tumors and aggressive cancers. Company announcements highlight clinical progress, strategic transactions, and regulatory milestones that shape the outlook for the ADXS symbol on the OTCQX market.
News items include detailed updates on AL102, Ayala’s investigational oral gamma secretase inhibitor for desmoid tumors, and the pivotal RINGSIDE Phase 2/3 trial. Releases discuss Phase 2 efficacy and safety data, the design of the Phase 3 registration segment, and U.S. FDA designations such as Fast Track and Orphan Drug status. Additional coverage describes the integration of aspacytarabine (BST-236), a novel anti-metabolite for unfit acute myeloid leukemia (AML), into Ayala’s pipeline following its merger with Biosight Ltd.
Investors and observers can also follow corporate and asset-level transactions through this news feed. Ayala has reported a definitive asset purchase agreement with Immunome, Inc. to acquire AL102 and AL101, and an asset purchase agreement with OS Therapies, Inc. to acquire its listeria monocytogenes-based immuno-oncology programs and related intellectual property assets, including lung and prostate cancer programs. Another key disclosure is Ayala’s Form 15 filing to deregister its common stock and suspend SEC reporting obligations.
By reviewing Ayala’s news, readers can see how the ADXS story has combined oncology drug development, mergers, and asset sales. The feed is useful for tracking clinical milestones in desmoid tumors and AML, understanding which external companies are now advancing former Ayala assets, and monitoring structural changes such as the merger with Biosight and the transition away from SEC periodic reporting. Bookmarking this page helps users quickly locate historical press releases and transaction announcements related to Ayala Pharmaceuticals and the ADXS ticker.
OS Therapies (NYSE-A: OSTX) has entered into an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.
The deal, valued at $0.5 million in cash and $7.5 million in OSTX shares, eliminates milestone payments and reduces royalty obligations for OST-HER2. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. The monthly burn rate is approximately $0.4M.
OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential approval and Priority Review Voucher by end of 2025. The company is prohibited from issuing shares for 6 months and suspended equity line usage below $12.00 per share.
OS Therapies (NYSE-A: OSTX) has entered an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.
The deal involves a $0.5 million cash payment and $7.5 million in OSTX common shares. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential FDA approval and Priority Review Voucher by end of 2025.
The agreement eliminates milestone payment obligations and reduces royalty rates for OST-HER2. The company's current burn rate is approximately $0.4M monthly, and they are prohibited from issuing shares for capital raising for 6 months and below $12.00 per share.
Ayala Pharmaceuticals, a clinical-stage oncology company, has filed a Form 15 with the SEC to deregister its common stock under the Exchange Act and suspend reporting obligations. This move will make the company no longer a public reporting entity once the Form 15 is effective.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.